Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VistaGen Therapeutics ( (VTGN) ) just unveiled an announcement.
On April 1, 2026, VistaGen Therapeutics, Inc. notified Nasdaq that it had fallen out of compliance with Nasdaq Listing Rule 5605(c)(2) after director Mary Rotunno’s resignation that day reduced its Audit Committee from three independent members to two. The company’s Nasdaq Capital Market listing remains unaffected for now, and under Nasdaq’s cure provisions VistaGen has until the earlier of its next annual shareholder meeting or up to one year from April 1, 2026, to add a qualified director and restore Audit Committee compliance, a step that will be closely watched by investors and governance stakeholders.
VistaGen also informed Nasdaq that its board plans to regain full compliance with the audit committee membership rule within the allowed cure period, signaling an intent to stabilize its governance structure. The temporary non-compliance underscores the sensitivity of Nasdaq-listed companies to board changes and places near-term focus on VistaGen’s director recruitment and corporate governance actions.
The most recent analyst rating on (VTGN) stock is a Sell with a $0.54 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
The score is held down primarily by sustained large losses and heavy cash burn on minimal revenue, combined with a weak long-term price trend and negative MACD. Neutral-to-mixed clinical/program updates and low leverage provide some support, but are outweighed by delisting risk and the PALISADE-3 setback.
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies in the life sciences sector. The company’s shares are listed on The Nasdaq Capital Market, subject to Nasdaq’s corporate governance and listing standards for board and committee composition.
Average Trading Volume: 909,218
Technical Sentiment Signal: Sell
Current Market Cap: $23.8M
For an in-depth examination of VTGN stock, go to TipRanks’ Overview page.